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Introduction: Previous research has debated whether red blood cell (RBC) transfusion is associated with decreased
or increased mortality in patients admitted to the intensive care unit (ICU). We conducted a systematic review and
meta-analysis to assess the relationship of RBC transfusion with in-hospital mortality in ICU patients.
Methods: We carried out a literature search on Medline (1950 through May 2013), Web of Science (1986 through
May 2013) and Embase (1980 through May 2013). We included all prospective and retrospective studies on the
association between RBC transfusion and in-hospital mortality in ICU patients. The relative risk for the overall pooled
effects was estimated by random effects model. Sensitivity analyses were conducted to assess potential bias.
Results: The meta-analysis included 28,797 participants from 18 studies. The pooled relative risk for transfused
versus nontransfused ICU patients was 1.431 (95% CI, 1.105 to 1.854). In sensitivity analyses, the pooled relative risk
was 1.211 (95% CI, 0.975 to 1.505) if excluding studies without adjustment for confounders, 1.178 (95% CI, 0.937 to
1.481) if excluding studies with relative high risk of bias, and 0.901 (95% CI, 0.622 to 1.305) if excluding studies
without reporting hazard ratio (HR) or relative risk (RR) as an effect size measure. Subgroup analyses revealed
increased risks in studies enrolling patients from all ICU admissions (RR 1.513, 95%CI 1.123 to 2.039), studies without
reporting information on leukoreduction (RR 1.851, 95%CI 1.229 to 2.786), studies reporting unadjusted effect
estimates (RR 3.933, 95%CI 2.107 to 7.343), and studies using odds ratio as an effect measure (RR 1.465, 95%CI 1.049
to 2.045). Meta-regression analyses showed that RBC transfusion could decrease risk of mortality in older patients
(slope coefficient −0.0417, 95%CI −0.0680 to −0.0154).
Conclusions: There is lack of strong evidence to support the notion that ICU patients who receive RBC transfusion
have an increased risk of in-hospital death. In studies adjusted for confounders, we found that RBC transfusion
does not increase the risk of in-hospital mortality in ICU patients. Type of patient, information on leukoreduction,
statistical method, mean age of patient enrolled and publication year of the article may account for the disagreement
between previous studies.* Correspondence: pingyin2000@126.com
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Anemia is highly prevalent among critically ill patients
[1]. Nearly 60% of the patients admitted to intensive care
units (ICUs) had a baseline hemoglobin (Hb) level less
than 12 g/dL and 30% less than 9 g/dL [2-4]. Anemia
persisted throughout the duration of their ICU stay and
long after ICU discharge [5]. Anemia could lead to a
decreased tissue oxygen delivery capacity, and is asso-
ciated with poor outcomes, including acute myocardial
infarction, heart failure, chronic kidney disease and risk of
death [6-10].
Transfusion of red blood cells (RBCs) has been one of
the most important treatments in clinical practice to
improve tissue oxygenation. In the CRIT study, 44% of
patients admitted to ICU received at least one RBC treat-
ment and the mean time to first transfusion was 2.3 ±
3.7 days [3]. However, over the last two decades concerns
have been raised that the possible risk of blood transfusion
may outweigh the benefits. Studies in trauma, sepsis
and acute respiratory distress syndrome (ARDS) patients
reported a nonimprovement in tissue oxygen delivery
[11-13], or even a decreased oxygenation through the stor-
age and preparation of RBCs [14,15]. The use of allogeneic
blood is also associated with potential adverse effects,
including immunosuppression [16], risk for infection,
transfusion reactions [17] and transfusion-related acute
lung injury (ALI) (TRALI) [18]. Most seriously, blood
transfusion may be associated with higher mortality
[2,3,19]. A meta-analysis published in 2008 demonstrated
an association between RBC transfusion and mortality in
critically ill patients: 12 published studies were included,
and the pooled odds ratio (OR) was 1.7 (95% confidence
interval (CI), 1.4 to 1.9) [20]. However, this association has
recently been questioned. Some studies reported that RBC
transfusion was associated with a lower rate of mortality.
Sakr et al. reported a decreased risk of in-hospital death in
blood-transfused surgical ICU patients (relative risk (RR)
0.96, 95%CI 0.95 to 0.98), especially in patients aged from
66 to 80 years, in patients admitted to the ICU after non-
cardiovascular surgery, in patients with severe sepsis
and in patients with high simplified acute physiology
score II (SAPS II) or sepsis-related organ failure assess-
ment (SOFA) scores [21]. More recently, Park et al. found
a lower risk of in-hospital death in transfused patients
with severe sepsis and septic shock (HR 0.51, 95%CI, 0.39
to 0.69) [4]. Despite all the controversy, clinical prac-
tice had been improved by the growing recognition of
transfusion-related risks. Bilgin et al. and Hebert et al.
had reported decreased mortality among patients receiv-
ing prestorage leukoreduced blood compared to patients
receiving nonfiltered blood [22,23], indicating that leuko-
cytes from donated blood may be crucial in the develop-
ment of immune system suppression. Another transfusion
practice is using ‘fresh’ transfused RBCs instead of ‘old’blood; some studies suggested that the use of old stored
RBCs is a potential risk factor for mortality [24,25]. There
is also a transfusion practice for ICU patients considering
a low transfusion threshold safer. A multicenter, random-
ized controlled trial (RCT) by Hebert et al., comparing
liberal (Hb level, 10 to 12 g/dL) and restrictive (Hb level,
less than 7 g/dL) RBC transfusion strategy, showed that
the restrictive strategy could decrease rates of organ dys-
function, cardiac complications and mortality [26].
As research on the benefits and risks of RBC transfu-
sion gains popularity, however, the results from previous
studies remain confusing: is allogeneic RBC transfusion
beneficial or harmful to ICU patients? And what kind of
transfusion practices are effective in decreasing mortality?
We thus conducted a meta-analysis of published retro-
spective and prospective observational studies comparing
RBC transfused with nontransfused ICU patients to assess:
(1) all-cause in-hospital mortality rate and (2) risk factors
of death in transfused patient.Methods
Data sources and searches
We followed the Strengthening the Reporting of Obser-
vational Studies in Epidemiology (STROBE) statement
for observational studies [27]. We used a comprehensive
search strategy to identify all potentially relevant studies
by searching Medline, Web of Science and EMBASE.
Databases were searched regardless of language and geog-
raphy, and the published time restricted to 1980 through
31 May 2013. The search used terms (‘mortality’) AND
(‘blood transfusion’ OR ‘anemia’ OR ‘erythrocyte trans-
fusion’). To identify additional studies, reference lists of
retrieved articles were also evaluated.Study selection
Two reviewers (YZ and CL) independently reviewed
and extracted studies abided by the following inclusion
criteria: (1) studies on adult subjects, or patients aged
older than 16 years, (2) studies enrolling subjects from
ICUs (medical or surgical), (3) studies dividing subjects
into two groups according to whether they received
transfusion or not, and reporting results focused on all-
cause in-hospital mortality rate. For hospitalized ICU
patients, in-hospital mortality is a short-term mortality, as
Vincent et al. investigated that transfused patients admit-
ted to ICU had a mean hospital length of stay (LOS) of
15.8 (9.0) days [2], and Sakr et al. found that the hospital
LOS of surgical ICU patient was from 9 to 19 days, with a
mean value of 12 days [21]. So our review was focused on
in-hospital mortality of less than a month. Exclusion
criteria were as follows: (1) studies on senior subjects,
defined as aged more than 80 years, and (2) case reports
or reviews.
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and mortality were reviewed. All abstracts reporting on
the association between blood transfusion and mortality
or mobility were selected for full-text review.
Data extraction
The primary outcome of interest was in-hospital mor-
tality of transfused ICU patients comparing transfused
(exposed group) versus nontransfused ICU patients. While
extracting data, we found that except for ‘in-hospital
mortality’ rate, some studies reported a ‘28-day mortality’
rate or ‘30-day mortality’ rate, in our review both were
regarded as approximate ‘in-hospital mortality’ rate. In
some of the studies, both adjusted results (OR, or RR, or
hazard ratio (HR)) and count data (the numbers of survi-
vors and nonsurvivors) were provided; or both propensity
matched results and no propensity matched results were
available. In these situations, we selected data for our
meta-analysis complying with the following rules: (1) ad-
justed results had precedence over count data; (2) HR and
RR estimates had precedence over OR estimates; (3)
propensity matched results had precedence over no
propensity matched results. The secondary outcomes were
factors associated with transfusion status. We extracted
relevant data from the literature as follows: (1) the type of
reported effect size, (2) publication year, (3) adjustment
for confounder, (4) mean admission Hb level, (5) percen-
tage of patients transfused in ICU, (6) mean volume of
transfused RBCs per patient, (7) mean pretransfusion Hb
level, (8) mean admission APACHE II score, (9) leukode-
pleted blood measurement, (10) mean age of patients, and
(11) type of patient.
Study quality assessment
The Strengthening the Reporting of Observational Studies
in Epidemiology (STROBE) statement for observational
studies [27] was used to assess the quality of the included
studies. The STROBE statement provided a checklist of
six domains including title and abstract, introduction,
methods, results, discussion and other information sec-
tions of articles to assess the quality of the observational
studies. Each of these domains was evaluated as low or
high risk of bias. Overall quality of the article was assessed
as low (high risk of bias in more than five domains), me-
dian (high risk of bias in three or four domains), high
(high risk of bias in one or two domains) and very high
(high risk of bias in none of the domains). Only primary
outcome (all-cause in-hospital mortality) was used to as-
sess the risk of bias.
Data synthesis and analysis
We used comprehensive meta-analysis software version
2.0 (Biostat, Englewood, NJ, USA) [28] to estimate pooled
effect size. RR was chosen as the common measurementof association across studies, and a random effects model
was used to generate a pooled RR estimate. HR was
considered as RR directly. OR was transformed into
RR if feasible. If effect estimates of mortality were not
available from the original article, then the effect size
was derived from the standard 2 × 2 table. The method
used for transformation from OR to RR was according to
Zhang et al. [29]:
RR ¼ OR= 1−P0ð Þ þ P0  ORð Þ½  ð1Þ
And the standard error of logRR is:
SE logRRð Þ ¼ SE logORð Þ  logRR=logOR ð2Þ
P0 represent the mortality rate in the nonexposed
group.
When P0 was not available, then OR was directly con-
sidered as RR. Because the transformation can underesti-
mate the variance of the RR derived from the OR [30], a
sensitivity analysis was performed excluding studies that
did not report adjusted RR or HR as the effect size. An-
other sensitivity analysis was performed excluding studies
with low or median study quality. Meta-regression ana-
lyses using unrestricted maximum likelihood model were
performed to assess the factors explaining the heterogen-
eity of risk ratios across studies. Stratified analyses were
performed to assess the impact of transfusion status and
mortality. Forest plots were constructed for selected stud-
ies, and Q statistic and I2 index were calculated to assess
heterogeneity of outcome measures across studies. Begg’s
rank correlation test and funnel plots were performed
to detect publication bias through visual inspection.
We assessed small study effect through the trim-and-fill
method.
Ethical approval
This study was reviewed and approved by the research
ethics committee of School of Public Health, Tongji
Medical College, Huazhong University of Science and
Technology, Wuhan, China on 25 February 2013. Consent




The initial literature search yielded 978 studies (Figure 1).
The titles and abstracts were examined independently by
two authors to identify potentially relevant studies. After
preliminary screening, 115 studies were left for full-text
review. By searching potentially relevant articles from
references, we further identified 11 studies for full-text
review, but none of them met the inclusion criteria.
Finally, 18 studies (28,797 participants) were identified
as relevant to the investigation of mortality of transfused
Figure 1 Details of study selection for systematic review.
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Eight studies were prospective and the other ten re-
trospective. For one study [31], the authors reported an
obvious wrong effect size, with the OR 2.46, and its 95%
CI 3.17 to 11.56. We calculated the crude effect value
through count data, and the crude OR (95%CI) was 5.33
(3.17 to 11.56). Table 1 provides detail information of
the 18 included studies [2-4,19,21,31-43].
Risk of bias assessment
The risk of bias assessment is represented in Figure S1 in
Additional file 1. We found that, title/abstract, introduc-
tion, results and discussion sections had a low risk of bias,
other information had a median risk of bias and methods
had a high risk of bias. Only one study did not indicate
the study’s design clearly [31]. Two studies did not discuss
limitations of the study and take any sources of potential
bias or imprecision into account [31,32]. Analyses of sub-
groups were not reported in three studies [32,42,43];
eleven studies did not provide information on handling of
missing data. Six studies reached very high overall quality
[2,34,35,37,39,41], nine studies reached high overall
quality [4,19,21,33,36,38,40], and the other three studies
reached median overall quality [31,32,42], no study reached
low overall quality. All risk of bias assessments wereconducted by two authors (YZ and CL). Disagreements
were resolved by consensus.
Synthesis of results
The overall pooled risk ratio of in-hospital mortality of
transfused patients compared to nontransfused was about
1.431 (95%CI, 1.105 to 1.854) (Figure 2).
Sensitivity analyses were presented in Table 2. When
excluding studies that did not adjust for any confounding
factors, the estimated association of RBC transfusion with
in-hospital mortality was null (RR 1.211, 95%CI, 0.975 to
1.505) (Figure 3). When we excluded studies with median
or low quality, there was also no association (RR 1.178,
95%CI, 0.937 to 1.481) (Figure 4). When we excluded
studies without reporting HR or RR as the effect size
measurement, still there was no significant association
(RR 0.901, 95%CI 0.622 to 1.305) (Figure 5). Subgroup
analyses were stratified by type of study patients, type of
reported effect size, confounder adjustment methods and
leukodepleted blood measurement (Table 3) (Figure S2 in
Additional file 2, Figure S3 in Additional file 3, Figure S4
in Additional file 4 and Figure S5 in Additional file 5).
Results of subgroup analyses suggested that blood trans-
fusion was a risk factor in studies enrolling patients from
all ICU admissions (RR 1.513, 95%CI 1.123 to 2.039),
Table 1 Details of studies included in meta-analysis (n = 18)
Study Study designation Inclusion population Exclusion population Adjustment for confounding
Vincent et al. [2] Prospective, multiple center, observational
study in western Europe
All ICU patients Not reported Patients’ admission variables
Corwin et al. [3] Prospective, multiple center, observational
cohort study in the United States
Not reported Admission to a pediatric, cardiothoracic,
cardiac, neurologic, or burn ICU; renal
failure on dialysis
Propensity to receive a transfusion
Robinson et al. [32] Retrospective, observational study Not reported Patients with blunt hepatic, splenic,
or both injuries
Shock indices and associated
injury severity
Croce et al. [31] Retrospective, observational study Patients with blunt injury and ISS <25,
survival of at least 48 hours, and no
blood transfusion within the first
48 hours from admission
Patients who received any transfusion
within the first 48 hours from
admission, ISS > =25
We use original numbers to analyze
RR, because the author reported
a distracting result (OR2.46,95%CI,
3.17 to 11.56)
Taylor et al. [19] Prospective, observational, cohort study All ICU admissions Not reported Unadjusted
Netzer et al. [33] Prospective, cohort study Patients with ALI/ARDS Patients were excluded if they had current
or prior congestive heart failure, respiratory
disease, or conditions that mimicked ALI/ARDS,
including vasculitis with diffuse alveolar
hemorrhage; were burned 30% of total body
area; or were lung or bone marrow recipients.
Age, gender, APACHE III score, and
precipitating event
Ruttinger et al. [34] Retrospective, observational cohort study All consecutive cases admitted
immediately or delayed after a
surgical procedure
Patients who had not undergone surgery
during their present hospital stay and who
had been admitted only for medical reasons,
and patients with a rapidly fatal clinical course
or with minimal disease severity
Admission variables, maximum APACHE II
score, maximum number of failing
organs, duration of invasive ventilation,
duration of catecholamine therapy,
and duration of renal replacement
therapy
Vincent et al. [35] Prospective, multicenter, observational
study
All ICU patients Not reported Sex and age, type of admission, main
medical history, fluid balance, SAPS II,
and severity of organ dysfunction on
admission as SOFA score
Bochicchio et al. [36] Prospective Trauma patients admitted >48 hours
to the ICU
Not reported Age, sex, race, and ISS
Bursi et al. [37] Retrospective observational study Stable patients after elective major
vascular surgery
Patients who had hemorrhagic hypovolemic
shock requiring emergency RBC transfusion,
severely anemic
Baseline characteristics, surgical risk,
bleeding, presence of anemia, and
propensity to receive transfusion
Engoren et al. [38] Retrospective study All ICU patients Cardiac surgical patients APACHE II scores and propensity to
receive a transfusion
Sakr et al. [21] Retrospective study All surgical ICU patients Not reported Patients’ propensity to receive a
transfusion
Parsons et al. [39] A secondary analysis Patients with new-onset ALI,
sepsis and shock
Patients with trauma or multiple transfusion Age, sex, race, randomization arm












Table 1 Details of studies included in meta-analysis (n = 18) (Continued)
Sheth et al. [40] Retrospective, observational cohort study Patients with intracerebral
hemorrhage
Patients younger than 18 years of age or with
ICH secondary to antecedent head trauma,
acute ischemic stroke with hemorrhagic
transformation, brain tumor, vascular
malformation, venous thrombosis, vasculitis
of the central nervous system, hematological
malignances, blood dyscrasia, or coagulopathy
Anemia, warfarin use, admission GCS
score, hematoma volume, hematoma
location, and DNR/CMO status
Park et al. [4] Prospective, multicenter observational study Patients with severe sepsis or
septic shock
Not reported Propensity to receive a transfusion
Brophy et al. [41] A cross-sectional retrospective study Anemia and renal dysfunction Patients with anemia of neoplastic diseases or
those receiving chemotherapy
Age, race, sex, ICU LOS, ESA use,
transfusion status, mechanical ventilation
or CPAP status, vasopressor use, severity
of, illness, and presence of, following
comorbid conditions, GI bleed,
sepsis, and neurologic injury.
Silva et al. [42] Prospective observational cohort study All ICU admissions Acute coronary syndrome, ischemic stroke,
acute hemorrhage, prior transfusion, pregnant
women and Jehovah’s Witnesses
Sex, origin, previous disease,
ventilation mode
Sekhon et al. [43] Retrospective cohort study Severe TBI patients Nontraumatic etiology, consciousness,
concomitant traumatic quadriparesis
Age, admission GCS score, insertion
of EVD, mean 7-day hemoglobin
APACHE, acute physiology and chronic health evaluation; CPAP, continuous positive airway pressure; DNR/CMO, do not resuscitate/comfort measures only; ESA, erythropoiesis-stimulating agents; EVD, external ventricular drain;
GCS, Glasgow coma score; GI, gastrointestinal; ICU, intensive care unit; LOS, length of stay; OR, odds ratio; RBC, red blood cells; RR, relative risk; SAPS, simplified acute physiology score; SOFA, sepsis-related organ failure












Figure 2 Association between red blood cell transfusion and in-hospital mortality.
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95%CI, 1.049 to 2.045), studies that did not adjust for
any confounders (RR 3.933, 95%CI 2.107 to 7.343)
and studies that did not provide available information
on leukoreduction (RR 1.851, 95%CI, 1.229 to 2.786),
while other subsets of studies suggested that RBC transfu-
sion was not associated with mortality.
To assess factors responsible for heterogeneity of effect
sizes across studies, we conducted meta-regression ana-
lyses. Six potential factors (publication year, mean admis-
sion Hb level, mean units transfused per patients, mean
pretransfusion Hb level, mean admission acute physiology
and chronic health evaluation II (APACHE II) score, and
mean age of patients) were considered. The results sug-
gested that publication year (coefficient −0.1056, P = 0.048)
and mean age of patient (coefficient −0.0417, P = 0.002)
had a significant influence. Table 4 summarizes the meta-
regression analyses. In our meta-analysis, only two of the





Excluded studies did not give
confounder-adjusted estimates
2 [19,31] 1
Excluded studies got a ‘moderate’
or ‘low’ risk of bias
3 [31,32,42] 1
Excluded studies did not reported
RR or HR as effect size measurement
12 [3,19,31-34,36,39-43] 6
CI, confidence interval; HR, hazard ratio; RR, relative risk.duration of RBCs [19,34], we thus could not conduct ana-
lysis on this topic.Publication bias
There was significant heterogeneity (P = 0.007) across
studies. Visual inspection of the funnel plot (Figure S6 in
Additional file 6) indicated the presence of a moderate
publication bias. Begg’s test suggests that significant publi-
cation bias was not likely (P = 0.570). Furthermore, when
looked for missing studies using the trim-and-fill random
effects model, no studies needed to be imputed.Discussion
Whether RBC transfusion is linked to higher or lower
mortality in critically ill patients has been a matter of de-
bate for more than a decade. Our review was aimed to
determine whether allogeneic RBC transfusion is benefi-









6 1.211 (0.975 to 1.505) 114.881, P <0.01 86.943
5 1.178 (0.937 to 1.481) 144.866, P <0.01 90.336
0.901 (0.622 to 1.305) 31.039, P <0.01 91.391
Figure 3 Association between red blood cell transfusion and in-hospital mortality, excluding studies that did not use any adjustment
for confounding.
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The main findings are as follows.
a. There is no consistent evidence linking RBC
transfusion to in-hospital mortality in ICU patientsFig
lowThe initially overall pooled results suggested that
allogeneic blood transfusion was associated with an
11% to 85% increased risk for in-hospital mortality.
However, after excluding studies with unadjusted
estimates only [19,31] or studies with median overall
quality [31,32,42], the association became null.ure 4 Association between red blood cell transfusion and in-hospita
quality.Therefore, we could not draw a definitive conclusion.
The results of sensitivity analyses suggested that such
risk association may be attributable to studies without
adjustment for confounders. In studies adjusted for
confounders, studies that reached effect size by
using the Cox regression model, and studies that
implemented detailed information about leukodepleted
blood measurement, we found that RBC transfusion
did not increase risk of in-hospital death.
b. There is no evidence indicating that RBC








Figure 5 Association between red blood cell transfusion and in-hospital mortality, excluding studies not reporting hazard ratio or
relative risk as the effect size measurement.
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trauma and surgical reasons.
Type of patients is an extremely important
confounder for survival after RBC transfusion.
Different types of patients have different responses
to RBCs transfusion. For example, age of transfused
RBCs could potentiate the risk association of volume
of RBC transfused in trauma patients, but less so in
other types of patients [44,45]. In our subgroup
analysis, we separate enrolled studies into four
groups according to patients’ population: all ICU
admissions (seven studies), sepsis and shock (twoble 3 Details of subgroup analysis of pooled risk ratio (95%CI) f
Number of studies included Effect size (95%C
pe of patient
All ICU 7[2,3,19,32,35,38,42] 1.513 (1.123 to 2.0
Sepsis and shock 2[4,39] 0.831 (0.203 to 3.4
Surgical 3[21,34,37] 1.174 (0.682 to 2.0
Trauma 3[31,36,43] 2.705 (0.815 to 8.9
Other 3[33,40,41] 0.940 (0.417 to 2.1
utcome measurement
Count data 2 [19,31] 3.969 (2.023 to 7.7
OR 10 [2,3,32-34,36,39-42] 1.465 (1.049 to 2.0
RR and HR 6 [4,21,35,37,38,43] 0.901 (0.622 to 1.3
justment
Unadjusted 2 [19,31] 3.933 (2.107 to 7.3
No propensity matched
but multiple adjusted
9 [2,32-34,39-41,43] 1.358 (0.965 to 1.9
opensity score matched 7 [3,4,21,35,37,38,42] 1.089 (0.767 to 1.5
ukoreduced usage
Not reported 11 [31-34,36,37,39-43] 1.851 (1.229 to 2.7
<50% 3[2,4,19] 1.155 (0.583 to 2.2
~76% 2 [3,35] 0.966 (0.412 to 2.2
~100% 2 [21,38] 1.031 (0.452 to 2.3
, confidence interval; HR, hazard ratio; ICU, intensive care unit; RR, relative risk.studies), surgical (three studies), trauma
(three studies), and others (three studies, one on
patients with ALI or ARDS, one on patients with
intracerebral hemorrhage, and one on patients with
anemia and renal dysfunction). As presented in
Table 3, the results suggested that there was no
association between RBC transfusion and mortality
in sepsis and shock, surgical, trauma and ‘other’
patients. The pooled overall effect estimate of
seven studies on all ICU admissions was significant
(RR 1.513, 95%CI 1.123 to 2.039). However, in these
seven studies, we noticed that one study did notor in-hospital mortality
I) Homogeneity index, Q Between-study variability, I2
39) 39.822, P <0.01 84.933
13) 8.041, P = 0.005 87.563
23) 6.793, P = 0.033 70.556
73) 30.695, P <0.01 93.484
16) 15.505, P <0.01 87.101
88) 28.936, P <0.01 96.544
45) 30.191, P <0.01 70.190
05) 31.039, P <0.01 91.391
43) 28.936, P <0.01 96.544
10) 25.626, P <0.01 68.782
46) 60.523, P <0.01 90.086
86) 86.863, P <0.01 88.488
90) 52.156, P <0.01 96.165
67) 14.812, P <0.01 93.249
52) 1.261, P = 0.26 20.696
Table 4 Details of meta-regression of slope coefficients for in-hospital mortality
Number of studies Coefficient (95% CI) P value
Age of patient 18 [2-4,19,21,31-43] −0.0417 (−0.0680 to −0.0154) 0.002
Publication year 18 [2-4,19,21,31-43] −0.1056 (−0.2103 to −0.0009) 0.048
Admission Hb 9 [2-4,21,38-42] −0.1848 (−0.4343 to 0.0648) 0.147
Units transfused 12 [2,3,19,21,31,32,35-37,42,43] −0.1676 (−0.3856 to 0.0504) 0.132
Pretransfusion Hb 7 [2-4,21,34,42,43] −0.2157 (−0.8588 to 0.4275) 0.511
APACHE II 8 [2-4,21,34,38,40,42] 0.0202 (−0.0569 to 0.0973) 0.607
APACHE II, acute physiology and chronic health evaluation II; CI, confidence interval; Hb, hemoglobulin.
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of bias [19]. Actually, after excluding this study, we
observed a 7% reduction but still significant pooled
overall effect estimate (RR 1.406, 95% 1.016 to
1.945). In a large, multiple center study by Vincent
et al., admission type of patients were elective
surgery (41.4%), medical (32.6%), emergency surgery
(16.6%), trauma (7.6%) and other (1.6%) [2]. In our
analysis, we were unable to identify medical ICU
patients as an independent subgroup. Literature on
the safety of RBC transfusion in medical ICU
patients was poor. In the SOAP study, medical
admission was found to be an independent
predictor for risk of 30-day mortality in ICU patients
(RR 1.47, 95% 1.24 to 1.74) [35]. Further studies are
needed to identify whether medical admissions are
less tolerant of RBC transfusion than other patient
populations.
c. There is a lack of evidence on whether
leukodepleted RBC transfusion could reduce
in-hospital mortality in ICU patients.
Immunomodulating effects of transfused RBCs have
been suggested as potential cause of many adverse
effects [46]. Leukocytes from donated blood may
play a key role in immune system suppression;
however, the exact mechanism is unclear [47].
Studies had reported a decrease in mortality rate
among patients receiving prestorage leukoreduced
blood compared to patients receiving nonfiltered
blood [22,23]; however, a meta-analysis of 12 RCTs
comparing leukodepleted and nonleukodepleted
RBCs failed to identify an association between
leukoreduction and mortality (OR 1.14, 95%CI, 0.89
to 1.45) [48]. Of the eighteen studies included in our
review, only seven of them had information on
percentage of patients receiving nonfiltered blood.
Filtered RBCs were routinely used in two studies,
Sakr et al. [21] suggested that RBC transfusion was
independently associated with lower risk of mortality
(RR 0.96, 95%CI, 0.95 to 0.98) while Engoren et al.
[38] found no association. In our subgroup analyses,
studies were divided into four groups according to the
usage of leukoreduction. In a subset of 11 studies thatdid not report information on leukoreduction, the
pooled effect estimate suggested that RBC
transfusion was associated with higher mortality
(RR 1.851, 95%CI, 1.229 to 2.786); however, the
pooled effect estimates of other subgroups were not
significant, regardless of the degree of implementation
of leukodepleted blood (Table 3). Studies lacking
information on leukoreduction had a higher
risk of in-hospital mortality. Because of insufficient
information, we cannot tell whether the use of
leukodepleted blood could decrease mortality in
transfused patients. Another possible explanation is
that studies lacking leukoreduction information also
had lower qualities, hence indicating high
risk of bias. We recommend that further studies
should take leukoreduction implementation
into consideration.
d. Study and statistical analysis methods are of
considerable importance in explaining the
association between RBC transfusion and in-hospital
mortality.
To model the association between RBC transfusion
and in-hospital mortality, 10 of the 18 included
studies used multivariable logistic regression, and
reported OR as the outcome measurement. Pooled
effect estimate of this subset of studies found that
there is a risk association between RBC transfusion
and mortality (RR 1.465, 95%CI, 1.049 to 2.045). In
contrast, in five studies used Cox regression, there
was no independent association between RBC
transfusion and mortality (RR 0.901, 95%CI,
0.622 to 1.305). This may be because that
selection of statistical model may have effect
on the final result. As logistic regression did
not take time-dependent variables into
consideration, with increasing follow-up time,
the logistic regression coefficients become less
reliable [49]. For the same transfusion data,
treating transfusion and living status as a
time-dependent variable or not may result in
different conclusions. Our review suggests that
the statistical analysis method may cause disagreement
between previous studies.
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severely ill patients were more likely to have
comorbidities after RBC transfusion [2,4]. The
quality of a study relies on the completeness of data
on possible confounders [34]. Patients’ admission
characteristics and disease severity are two major
confounders that can have an impact on transfused
patients’ risk of death. Multivariable confounder-
adjustment analyses and propensity score analyses
are implemented in most of the studies to control
imbalances between transfused and nontransfused
groups. Under propensity matched groups, patients
were matched by their probability to receive a
transfusion, thus statistically reducing confounding
bias. Previous findings revealed that propensity score
analysis could produce estimates that were more
precise and robust than regular logistic regression
while there were seven or fewer events per
confounding variables, but might produce unstable
estimates when events per confounder were more
than eight [50]. Most of our included studies
reported multivariable confounder-adjusted
estimates (Table 3), and the mostly used confounders
in adjustments were patient characteristics at
admission including age, gender and admission
symptom score; seven studies used propensity score
analyses. Subgroup analyses of the seven propensity
score matched studies and the other nine no
propensity score matched confounder-adjusted studies
all showed no association between RBC transfusion
and death (RR 1.089, 95%CI, 0.767 to 1.546; RR 1.358,
95%CI, 0.965 to 1.910 respectively), while the other
two studies with unadjusted effect estimates only
showed an increased risk (RR 3.933, 95%CI 2.107 to
7.343). This suggests that studies that did not fully
adjust for confounders may overestimate the negative
effects of RBC transfusion. This finding supported the
view of Ruttinger et al. [34] that RBC transfusion may
be only a surrogate marker for disease severity and is
not causally related to mortality. Ruttinger’s study
even suggested the pitfalls of propensity score and
multivariate analyses; both cannot adjust for
unobserved or unknown confounders, and not all
factors that may influence transfusion practice had
been collected. Ruttinger considered variables
reflecting disease severity during ICU stay, and found
that the number of RBC transfusion units was
associated with increased mortality, and the
association attenuated but persisted while only
adjusted for admission variables. When controlling for
variables of disease severity during ICU stay, this
association vanished. Disease severity during ICU stay
might be particularly important. We suggest that
further research should take this into consideration.In our review, we performed meta-regression analyses
to assess whether the mean number of units of blood
transfused, mean admission Hb level and mean
admission symptom score could explain disagreement
between study results. Mean number of units of RBC
transfused were reported in twelve studies, mean
admission Hb level were reported in nine studies,
mean APACHE II score were reported in eight studies,
mean SOFA score were reported in four studies
[2-4,42], and mean SAPS II [35] and mean APACHE
III score [39] were reported in only one study,
respectively. Results of meta-regression failed to
identify significant association across studies for
mean number of units of RBC transfused
(coefficient −0.1676, 95%CI, −0.3865 to 0.0504),
mean admission Hb level (coefficient −0.1848,
95%CI, −0.4343 to 0.0648) and mean APACHE II
score (coefficient 0.0202, 95%CI, −0.0569 to 0.0973).
In other words, these variables could not explain
the disagreement across studies.
e. Blood transfusion may decrease risk of mortality in
older patients.
The slope estimate was significant −0.0417
(95%CI, −0.0680 to −0.0154) (Figure S8 in
Additional file 7), suggesting that with older age,
transfused patients had better chances of survival.
This is interesting since age has long been known as
a predictor for worse outcomes including mortality.
We speculate that this may be due to the following
reasons. (1) Older patients and younger patients
have different etiology of anemia. Older patients
are more likely to have nutritional deficiency,
chronic diseases and unexplained anemia [51].
Consequently, older patients and younger patients
may differ in disease severity and clinical
treatment. (2) Hb level may be a potential
explanation. Using World Health Organization
(WHO) definition of anemia (Hb level <13 g/dL
in men and <12 g/dL in women), the corrected
annual incidence of anemia increased with age
[52], and the study found that even a ‘higher’ Hb
level was associated with risk of death in older
people [53]. Older patients may have different
‘optimal’ Hb concentrations, a ‘mildly low’ and
‘low-normal’ Hb level may be well tolerated in
young patients, but not in older people [54,55].
Literature on patient’s age, survival and blood
transfusion is controversial in defining anemia in
older people. Although we identified a significant
association between mean age of patient and
survival, there was no strong evidence to support
this view. Further research could explore whether
blood transfusion is more effective in improving
survival in older patients.
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for RBC transfusion: articles tend to report lower
risk effect estimates.
The number of reports concerning such issues has
grown fast in recent years, as shown in Figure S7
in Additional file 8. The meta-regression analysis
produced a significant effect for publication year.
Recent studies are more likely to report relativity
lower risk ratios, indicating that RBC transfusion
might have gradually become safer [56]. Safety
concerns in RBC transfusion have emerged during
the past two decades along with clinical practice
changes [57]. The most important change in clinical
practice is the recognition that the decision to
transfuse should not be driven by a single Hb
threshold, but by the physiologic state of the
individual patient, presence of comorbidity,
cardiopulmonary physiologic parameters, and
evidence of blood loss [56,58]. In our meta-analysis,
seven studies from the years 2002 to 2012 had
reported average pretransfused Hb levels, and the
mean Hb levels ranged from 6.6 g/dL to 8.6 g/dL.
Meta-regression for pretransfusion Hb level
failed to identify the significance for risk of mortality
(coefficient −0.216, 95%CI −0.859 to 0.428).
Limitations
It should be noted that the present meta-analysis had
several limitations. First, all studies included in the
meta-analysis were observational studies. Limited by
study design, a causal relationship could not be deter-
mined. A convincible causal relationship needs further
research in large RCTs. Second, limited by our recognition
of exact mechanisms of transfusion-related complications,
the potential confounders for death were not fully adjus-
ted and may not all be included in our meta-analysis, this
may have led to potential risk of bias. Third, the number
of studies in subgroup and meta-regression analyses was
relativity small, and therefore produced unstable effect
estimates. Fourth, our study only focused on mortality
within one month, while patients with death after one
month of hospitalization may have high risk of transfu-
sion. Finally, publication bias may still exist from un-
published studies, and publications in sources out of our
literature search criteria.
Conclusions
Our systematic review and meta-analysis summarized
published literature on the relation between RBC trans-
fusion and in-hospital mortality of ICU patients. We
conclude that there is a lack of evidence to support the
claim that ICU patients who receive RBC transfusion
have an increased risk of in-hospital mortality. In studies
that have adjusted for confounders, RBC transfusion didnot increase the risk of in-hospital mortality in ICU
patients. The review also suggests possible reasons to
explain the discrepancies between previous studies. Our
finding points to the need to identify risk factors for
mortality in patients admitted to the medical ICU to ac-
count for all possible confounders for mortality. RCTs
are warranted to provide convincible evidence of casual
association.Key messages
 There was no consistent evidence to link RBC
transfusion with mortality in ICU patients.
 In studies that had adjusted for confounders, RBC
transfusion was not associated with in-hospital
mortality in ICU patients.
 The discrepancies on risk of mortality and RBC
transfusion between previous studies may be due
to different types of patients, information on
leukoreduction, study design and statistical methods,
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